Description of Invention:
This technology involves the isolation and identification of Helicobacter within fecal matter. The technology provides for the methods and nucleic acid primer reagents and sequences specific for H. pylori. Specifically, it addresses the identification of the common human species of H. pylori. H. pylori is a major infectious agent of the human gastric intestinal tract, affecting about 50% of the world population with various degrees of severity. H. pylori infection is associated with 95% of duodenal ulcers and 80% of gastric ulcers. Without treatment, 80% of duodenal ulcers will return. Further, gastric ulcers have been linked as precursors to the more life-threatening gastric cancers.
Current diagnostics are expensive, invasive, or require the patient to ingest radioactive substances. The technology presented provides for a quick, specific, inexpensive, non-invasive method for diagnosis of H. pylori infection as well the ability to repeat such tests for patient follow up on treatment effectiveness. Also included is the ability to develop kits for commercial purposes.
Inventors:
Dougbeh C. Nyan et al. (NIDDK)
Patent Status:
DHHS Reference No. E-146-2002/0 --
U.S. Provisional Application No. 60/468,341 filed 06 May 2003
PCT Application No. PCT/US2004/14374 filed 06 May 2004, which published as WO 2005/001109 on 06 Jan 2005
For Additional Information Please Contact: Robert M. Joynes J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)594-6565
Email: joynesr@mail.nih.gov
Fax: (301) 402-0220
